Generation Bio's Q3 net loss narrows to $5.5 mln

Generation Bio

05/11/2025 21:44

Overview

Generation Bio Q3 net loss improves to $5.5 mln from $15.3 mln last year

Company's collaboration revenue declines sharply in Q3

Lease settlement results in $25.5 mln gain on lease termination

Outlook

Company expects cash reserves to fund operations for foreseeable future

Result Drivers

LEASE SETTLEMENT - Co recorded a $25.5 mln gain from a lease termination settlement

INCREASED EXPENSES - R&D and G&A expenses rose due to ongoing investments

COLLABORATION REVENUE DECLINE - Co's collaboration revenue fell significantly in Q3

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$1.59 mln
Q3 EPS
-$0.82
Q3 Net Income
-$5.52 mln
Q3 Basic EPS
-$0.82
Q3 Operating Expenses
$8.30 mln
Q3 Operating Income
-$6.71 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Generation Bio Co is $13.50, about 61.1% above its November 4 closing price of $5.25

Press Release: ID:nGNX2l50tv

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)